A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

Trial Profile

A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Status changed from suspended to active, no longer recruiting.
    • 26 Jun 2017 Biomarker data will be presented at the European Society of Gynaecologic Oncology (ESGO) meeting 2017, according to an Advaxis media release.
    • 13 Jun 2017 According to an Advaxis media release, the company plans to present data from this trial at the International Meeting of the European Society of Gynecological Oncology (ESGO) in November.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top